The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid an accelerating wave of SPAC mergers in biotechnology, Talawar Therapeutics and JATT II Acquisition Corp. (NASDAQ: JATT) announced a definitive business combination to create a publicly listed biotech firm. According to reports, the deal includes an oversubscribed $225 million concurrent PIPE that will fund lead candidate TALA-125 through a Phase 2b proof-of-concept readout in the second half of 2028. TALA-125 is a novel anti-IL-13 × anti-IL-18 bispecific antibody for atopic dermatitis, with clinical entry expected in Q1 2027.
Sign in to access this content
Sign InThe transaction comes amid a broader SPAC wave in biotech, though many previous deals have struggled to meet projected valuations. The oversubscribed PIPE signals investor confidence in Talawar’s early-stage pipeline. Per market data, early-stage biotech valuations remain volatile and hinge on upcoming clinical trial results, making the success of TALA-125 critical.
Investors will monitor regulatory approvals and the deal's expected closing in the second half of 2026. Post-listing, the focus will shift to TALA-125’s Phase 1 initiation in Q1 2027, with the Phase 2b readout in H2 2028 as a key catalyst. No trading levels exist yet, but the stock will be driven by clinical progress and future trial outcomes.